These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31260944)

  • 21. [Multiple sclerosis associated with myasthenia gravis].
    Grinshteĭn AB; Griaznova EG; Shetekauri SA
    Sov Med; 1990; (7):110-1. PubMed ID: 2251551
    [No Abstract]   [Full Text] [Related]  

  • 22. Myasthenia gravis and associated autoimmune diseases in children.
    Tsao CY; Mendell JR; Lo WD; Luquette M; Rennebohm R
    J Child Neurol; 2000 Nov; 15(11):767-9. PubMed ID: 11108515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Difficulties in the diagnosis of myasthenia gravis].
    Ponomareva EN; Latysneva VIa; Sitnik GD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(11):1630-3. PubMed ID: 3434059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of humoral and cellular immune factors in neuromuscular block in myasthenia gravis.
    Namba T; Nakata Y; Grob D
    Ann N Y Acad Sci; 1976; 274():493-515. PubMed ID: 786115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell activity in multiple sclerosis and myasthenia gravis.
    Rauch HC; Montgomery IN; Kaplan J
    Immunol Invest; 1985 Oct; 14(5):427-34. PubMed ID: 4077156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-mediated rippling muscle disease and myasthenia gravis.
    Bettini M; Gonorazky H; Chaves M; Fulgenzi E; Figueredo A; Christiansen S; Cristiano E; Bertini ES; Rugiero M
    J Neuroimmunol; 2016 Oct; 299():59-61. PubMed ID: 27725122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis.
    Bond A; Corlett L; Nagvekar N; Jacobson L; Pantic N; Beeson D; Nicolle M; Vincent A; Newsom-Davis J; Spack E; Willcox N
    Biochem Soc Trans; 1997 May; 25(2):665-70. PubMed ID: 9191178
    [No Abstract]   [Full Text] [Related]  

  • 28. Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.
    Link J; Fredrikson S; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Feb; 35(2):197-203. PubMed ID: 7509140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mannose-binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders.
    Farrokhi M; Dabirzadeh M; Dastravan N; Etemadifar M; Ghadimi K; Saadatpour Z; Rezaei A
    Iran J Allergy Asthma Immunol; 2016 Jun; 15(3):251-6. PubMed ID: 27424141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple sclerosis with impaired neuromuscular transmission.
    Chaco J
    Confin Neurol; 1974; 36(3):182-5. PubMed ID: 4376477
    [No Abstract]   [Full Text] [Related]  

  • 31. NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome.
    Zarobkiewicz MK; Morawska I; Michalski A; Roliński J; Bojarska-Junak A
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myasthenia gravis.
    Linton DM; Philcox D
    Dis Mon; 1990 Nov; 36(11):593-637. PubMed ID: 2209357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexistence of systemic lupus erythematosus and myasthenia gravis.
    Killian PJ; Hoffman GS
    South Med J; 1980 Feb; 73(2):244-6. PubMed ID: 7355329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic aspects of neurologic and neuromuscular diseases.
    Smith DR; Weiner HL
    JAMA; 1997 Dec; 278(22):1956-61. PubMed ID: 9396658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal change disease in a patient with myasthenia gravis: A case report.
    Tsai JL; Tsai SF
    Medicine (Baltimore); 2016 Sep; 95(39):e5008. PubMed ID: 27684864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic aspects of neurological and neuromuscular diseases.
    Zweiman B; Arnason BG
    JAMA; 1987 Nov; 258(20):2970-3. PubMed ID: 3312680
    [No Abstract]   [Full Text] [Related]  

  • 37. Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?
    Rinaldi E; Consonni A; Guidesi E; Elli M; Mantegazza R; Baggi F
    Ann N Y Acad Sci; 2018 Feb; 1413(1):49-58. PubMed ID: 29341125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights in the autoimmunity of myasthenia gravis.
    De Baets MH
    Autoimmunity; 2010 Aug; 43(5-6):341-3. PubMed ID: 20380585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review.
    Sylvester J; Purdie G; Slee M; Gray JX; Burnet S; Koblar S
    J Neuroimmunol; 2013 Nov; 264(1-2):130-3. PubMed ID: 24041829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis.
    Cantor F
    PM R; 2010 May; 2(5):399-405. PubMed ID: 20656621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.